Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

NEXT STORY
Immuneering Added to the Nasdaq Biotechnology Index
PREV STORY
At 11.3% CAGR, Recombinant Vaccines Market Size [2021-2028] | is Expected to Reach USD 25.32 Billion
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD’s Pediatric Hexavalent Combination Vaccine

FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine    PARIS and KENILWORTH, ...

author_avatar
NASDAQ Market News

Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union

author_avatar
NASDAQ Market News

Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification

Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019NEW YORK, ...

author_avatar
NASDAQ Market News